The circadian timing system: A coordinator of life processes

IEEE Engineering in Medicine and Biology Magazine

Volumn 27, Issue 1, 2008, Pages 17-19

  Lévi, Francis ^a,b,c,d  

^a Department of Georges Mathé ^*

^b French Academy of Technology

^c INSERM   (France)

^d FP6 Network of Excellence BioSim

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; VINDESINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL FUNCTION; CELL PROLIFERATION; CELL REGENERATION; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL PRACTICE; COLORECTAL CANCER; DNA REPAIR; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVITY; HUMAN; LOCOMOTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SUPRACHIASMATIC NUCLEUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL CLOCKS; CELL CYCLE; CELL PHYSIOLOGY; CHRONOBIOLOGY; CIRCADIAN RHYTHM; HUMANS; NEOPLASMS;

EID: 38549122298     PISSN: 07395175     EISSN: None     Source Type: Journal    
DOI: 10.1109/MEMB.2007.907361     Document Type: Article

References (22)

1. M. H. Hastings, A. B. Reddy, and E. S. Maywood, "A clockwork web: Circadian timing in brain and periphery, in health and disease," Nat. Rev. Neurosci., vol. 4, no. 8, pp. 649-661, 2003.
2. K. L. Toh, C. R. Jones, Y. He, E. J. Eide, W. A. Hinz, D. M. Virshup, L. J. Ptacek, and Y. H. Fu, "An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome," Science, vol. 291, no. 5506, pp. 1040-1043, 2001.
3. U. Schibler and P. Sassone-Corsi, "A web of circadian pacemakers," Cell, vol. 111, no. 7, pp. 919-922, 2002.
4. F. Lévi and U. Schibler, "Circadian rhythms: Mechanisms and therapeutic implications," Annu. Rev. Pharmacol. Toxicol., vol. 47, pp. 593-628.
5. E. Filipski, V. M. King, X. M. Li, T. G. Granda, M. C. Mormont, X. H. Liu, B. Claustrat, M. H. Hastings, and F. Lévi, "Host circadian clock as a control point in tumor progression," J. Natl. Cancer Inst., vol. 94, no. 9, pp. 690-697, 2002.
6. M. C. Mormont, J. Waterhouse, P. Bleuzen, S. Giacchetti, A. Jami, A. Bogdan, J. Lellouch, J. L. Misset, Y. Touitou, and F. Lévi, "Marked 24-h rest-activity rhythms are associated with better quality of life, better response and longer survival in patients with metastatic colorectal cancer and good performance status," Clin. Cancer Res., vol. 6, no. 8, pp. 3038-3045, 2000.
7. G. A. Bjarnason and R. Jordan, "Circadian variation in the expression of cell-cycle proteins in human oral epithelium," Am. J. Pathol., vol. 154, no. 2, pp. 613-622, 1999.
8. R. Smaaland, O. D. Laerum, K. Lote, O. Sletvold, R. B. Sothern, and R. Bjerknes, "DNA synthesis in human bone marrow is circadian stage dependent," Blood, vol. 77, no. 2, pp. 2603-2611, 1991.
9. T. G. Granda and F. Lévi, "Tumor-based rhythms of anticancer efficacy in experimental models," Chronobiol. Int., vol. 19, no. 1, pp. 21-41, 2002.
10. L. Fu, H. Pelicano, J. Liu, P. Huang, and C. C. Lee, "The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo," Cell, vol. 111, no. 1, pp. 41-50, 2002.
11. T. Matsuo, S. Yamaguchi, S. Mitsui, A. Emi, F. Shimoda, and H. Okamura, "Control mechanism of the circadian clock for timing of cell division in vivo," Science, vol. 302, no. 5643, pp. 255-259, 2003.
12. T. G. Granda, X. H. Liu, N. Cermakian, R. Smaaland, E. Filipski, P. Sassone-Corsi, and F. Lévi, "Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumour," FASEB J., vol. 19, no. 2, pp. 304-306, 2005.
13. E. Filipski, P. F. Innominato, M. W. Wu, X. M. Li, S. Iacobelli, L. J. Xian, and F. Lévi, "Effects of light and food schedules on liver and tumor molecular clocks," J. Natl. Cancer Inst., vol. 97, no. 7, pp. 507-517, 2005 .
14. T. G. Granda, E. Filipski, R. M. D'Attino, P. Vrignaud, A. Anjo, M. C. Bissery, and F. Lévi, "Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination," Cancer Res., vol. 61, no. 5, pp. 1996-2001, 2001.
15. T. G. Granda, R. M. D'Attino, E. Filipski, P. Vrignaud, C. Garufi, E. Terzoli, M. C. Bissery, and F. Lévi, "Circadian optimization of irinotecan and oxaliplatin efficacy in mice with Glasgowosteosarcoma," Br. J. Cancer, vol. 86, no. 6, pp. 999-1005, 2002.
16. C. Focan, "Rhythms of cancer chemotherapy," in Chronotherapeutics, P. Redfern, Ed. London, UK: Pharmaceutical Press, 2003, ch. 10, pp. 235-282.
17. F. Lévi, "Circadian rhythms in 5-fluorouracil pharmacology and therapeutic applications," in Fluoropyrimidines in Cancer Therapy, Y. Rustum, Ed. Totowa, NJ: Humana Press, 2003, pp. 107-128.
18. F. Lévi, "Circadian chronotherapy for human cancers," Lancet Oncol., vol. 2, no. 5, pp. 307-315, 2001.
19. M. C. Mormont and F. Lévi, "Cancer chronotherapy: Principles, applications and perspectives," Cancer, vol. 97, no. 1, pp. 155-169, 2003.
20. F. Lévi, R. Zidani, J. M. Vannetzel et al., "Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial," J. Natl. Cancer Inst., vol. 86, no. 21, pp. 1608-1617, 1994.
21. F. Lévi, R. Zidani, and J. L. Misset, for the International Organization for Cancer Chronotherapy, "Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer," Lancet, vol. 350, no. 9079, pp. 681-686, 1997.
22. S. Giacchetti, G. Bjarnason, C. Garufi, D. Genet, S. Iacobelli, M. Tampellini, R. Smaaland, C. Focan, B. Coudert, Y. Humblet, J. L. Canon, A. Adenis, G. Lo Re, C. Carvalho, J. Schueller, N. Anciaux, M. A. Lentz, B. Baron, T. Gorlia, and F. Lévi, on behalf the Chronotherapy Group of EORTC, "Phase III trial of 4-day chronomodulated vs 2-day conventional delivery of 5-fluorouracil, leucovorin and oxaliplatin as first line chemotherapy of metastatic colorectal cancer by the EORTC chronotherapy group," J. Clin. Oncol., vol. 24, no. 22, pp. 3562-3569, 2006.